View scientific program here (interactive) or here (pdf)
View the synoptic here
07h30 Welcoming coffee
-------------------------------------------------------------------------------------------------------
Epidemiology, genetics and pathophysiology of valvular diseases
Moderators: Per Eriksson & Victor Legrand
-------------------------------------------------------------------------------------------------------
08.00 Genetics and pathophysiology of bicuspid and tricuspid aortic valve disease. What we learned from the ASAP study?
Per Eriksson
08.15 Biomechanical implications of bicuspid aortic valve
Alessandro Della Corte 
08.30 Aortic root morphology in bicuspid and tricuspid aortic valve surgery
Anders Franco-Cereceda
08.45 Paradoxical low flow low gradient in aortic valve stenosis
Jean Dumesnil
09.00 Talks selected from submitted abstracts
09.00 Simultaneous detection of elevated matrix metalloproteinases in ascending aortic aneurysms in patients with bicuspid aortic valve disease
Mohamed Salah
09.05 Early cell changes and transforming-growth-factor-beta pathway alterations in the aortopathy associated with bicuspid aortic valve stenosis
M. Buonocore
09.10 Valve morphotype and aortic phenotype affect the progression of aortic dilatation in bicuspid aortic valve associated aortopathy
V. D’Oria
09.15 Clinical and echographic predictive values of the dilated aorta in patients with bicuspid aortic valve
Laure Gilis
09.20 Discussion
09.45 Coffee break
-------------------------------------------------------------------------------------------------------
Clinical management and treatment of valvular diseases
Moderators: Victor Legrand & Marc A. Radermecker
-------------------------------------------------------------------------------------------------------10.15 New ESC/EACTS guidelines in the management of asymptomatic severe aortic stenosis
Luc Pierard
10.35 TAVI indication and management of complications
Carlo Di Mario
10.55 Factors influencing the long term results of aortic valvuloplasty
Gebrine El Khoury
11.15 Talks selected from submitted abstracts
11.15 Surgical treatment of ascending aortic aneurysms in patients with bicuspid aortic valve disease
Vitalii Kravchenko
11.20 Subclavian TAVI: a single centre experience
KJ Griffin
11.25 Discussion
11.30 Debate and interactive discussions:
- Clinical case debate: for/against
Victor Legrand
- Aortic stenosis in octogenarian: TAVI vs. Surgery
Inez Rodrigus
12.00 Lunch
13.00 Symposium 
Perceval™ S. The Truly Sutureless Valve: 5-years Clinical Results And First BeNeLux Results
Jean-Olivier Defraigne
13.00 5-Years European Clinical Results with Perceval™ S
Bart Meuris
13.10 First Experiences with Perceval™ S.
Jean-Marc Marnette
13.20 A single center experience with Perceval in Maastricht
S. Kats
13.30 Minimal invasive approach trough Right-minithoracotomy: First Experiences
Mattia Glauber
13.40 Closing Remarks
Jean-Olivier Defraigne
-------------------------------------------------------------------------------------------------------
Recent advances and future directions of aortic diseases
Moderator: Frank Lederle
-------------------------------------------------------------------------------------------------------
14.00 Why the EVAR trials are misleading: EVAR is better than open repair in fit and unfit patients
Frank Veith
14.15 Introduction of AAA healing by a short administration of cyclosporine A: from the lab to a clinical trial in France
Eric Allaire
14.30 18 months doxycycline therapy for AAA stabilization: results of the Pharmaceutical Aneurysm Stabilization Trial (PHAST)
Jan Lindeman
14.45 AAA and inflammation: the problem or the solution?
Jan Lindeman
15.00 Final results of the VA Open vs. Endovascular Repair (OVER) trial for AAA
Frank Lederle
15.15 Does PET scan reliably predict AAA rupture?
Natzi Sakalihasan
15.30 The biomechanical AAA rupture risk
Christian Gasser
15.45 Regional mechanical properties of AAA tissue and finite element analysis of rupture risk
Tim McGloughlin
16.00 The role of HDL in AAA: a nation-wide case control study (N=50000) and a prospective cohort growth study of AAA diagnosed by population-based
screening (N=500)
Jes Lindholt
16.15 Discussion
16.35 Talks selected from submitted abstracts
16.35 Multidimensional analysis of growth of small Abdominal Aortic Aneurysms
Giampaolo Martufi
16.40 Multifactorial relationship between 18F-fluoro-deoxy-glucose positron emission tomography signalling and wall stress in unruptured aortic aneurysms
Alain Nchimi
16.45 The vitamin D receptor (VDR) is a weak moderator of vascular inflammation. A study of the abdominal aortic aneurysm
Arend-Jan Nieuwland
16.50 Sorafenib inhibits angiotensin II-induced aneurysm formation and progression in Apolipoprotein E-deficient mice
Badri Vijaynagar
16.55 Thiazolidinediones prevent aortic aneurysm and rupture: understanding the mechanism of action
Nicoletta Charolidi
17.00 Measuring the maximum diameter of native abdominal aortic aneurysms: review and critical analysis
Laurence Rouet
17.05 Young investigator awards and concluding remarks
Helena Kuivaniemi and Jean-Olivier Defraigne
17.30 Adjournment
